Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
213Bi-isotype control antibody
- Development stage
- Preclinical
- Lead developer
- Panacea Pharmaceuticals
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
213Bi-isotype control antibody is a radiolabeled monoclonal antibody used as a negative control in radioimmunotherapy (RIT) research. It consists of the alpha-emitting radioisotope Bismuth-213 (213Bi) conjugated to a non-specific, isotype-matched monoclonal antibody that does not target a specific antigen in the study system (e.g., human aspartyl (asparaginyl) β-hydroxylase). In preclinical studies for acute myeloid leukemia (AML), it is used to demonstrate that the cytotoxic effects of the targeted agent (such as 213Bi-DTPA-PAN-622) are due to specific antigen binding rather than non-specific radiation exposure. The antibody is typically modified with a chelator like DTPA to facilitate the binding of the 213Bi isotope.
- Other names
- 213Bi-DTPA-isotype control antibodyBismuth-213 labeled isotype control antibodyBismuth213 labeled isotype control antibodyBismuth 213 labeled isotype control antibody
Beyond the preview
Go deeper on 213Bi-isotype control antibody.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on 213Bi-isotype control antibody.